文献速递临床试验与 GCP

在单用二甲双胍或联用磺脲类仍未控制的2型糖尿病成人中,加用口服司美格鲁肽对比西格列汀对糖化血红蛋白的影响:PIONEER 3随机临床试验

Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial.
PubMed 文献 · JAMA · 2019-01-01

这项在14国206个中心开展的随机双盲双模拟3a期试验纳入1864例二甲双胍(联用或不联用磺脲类)未控制的2型糖尿病成人,比较每日一次口服司美格鲁肽3、7、14 mg与西格列汀100 mg。第26周时,司美格鲁肽7 mg/d和14 mg/d较西格列汀显著降低HbA1c和体重,3 mg/d对HbA1c的非劣效性未得到证实。

要点

  • 第26周司美格鲁肽7 mg/d和14 mg/d较西格列汀显著降低HbA1c,差值分别为-0.3%和-0.5%。
  • 第26周司美格鲁肽7 mg/d和14 mg/d较西格列汀显著降低体重,差值分别为-1.6 kg和-2.5 kg。
  • 司美格鲁肽3 mg/d对HbA1c的非劣效性未得到证实。

核心结论

  • 在二甲双胍联用或不联用磺脲类仍未控制的2型糖尿病成人中,口服司美格鲁肽7 mg/d和14 mg/d较西格列汀在26周内显著降低HbA1c,但3 mg/d剂量无显著获益。
  • 作者指出需进一步研究评估其在临床环境中的有效性。

研究设计与样本

  • 随机、双盲、双模拟、平行组、3a期试验,在14个国家206个中心开展,历时78周,时间为2016年2月至2018年3月。
  • 筛查2463例,随机化1864例二甲双胍联用或不联用磺脲类仍未控制的2型糖尿病成人。
  • 随机分为口服司美格鲁肽3 mg(n=466)、7 mg(n=466)、14 mg(n=465)或西格列汀100 mg(n=467)。
  • 司美格鲁肽以3 mg/d起始,每4周递增,先至7 mg/d再至14 mg/d,直至达到随机剂量。
  • 主要终点为HbA1c从基线至第26周的变化,关键次要终点为体重从基线至第26周的变化,两者在第52周和第78周作为额外次要终点评估。

主要发现

  • 随机化1864例患者平均年龄58岁(SD 10),平均基线HbA1c 8.3%(SD 0.9%),平均体重指数32.5(SD 6.4),女性879例(47.2%)。
  • 1758例(94.3%)完成试验,298例提前终止治疗(司美格鲁肽3 mg/d组16.7%、7 mg/d组15.0%、14 mg/d组19.1%、西格列汀组13.1%)。
  • 第26周,司美格鲁肽7 mg/d和14 mg/d较西格列汀显著降低HbA1c,差值分别为-0.3%(95%CI -0.4%至-0.1%)和-0.5%(95%CI -0.6%至-0.4%),P均<.001。
  • 第26周,司美格鲁肽7 mg/d和14 mg/d较西格列汀显著降低体重,差值分别为-1.6 kg(95%CI -2.0至-1.1 kg)和-2.5 kg(95%CI -3.0至-2.0 kg),P均<.001。
  • 司美格鲁肽3 mg/d对HbA1c的非劣效性未得到证实;第78周司美格鲁肽14 mg/d较西格列汀在两个终点上的降低均具有统计学显著差异。

关键数值与推荐

  • HbA1c非劣效性界值为0.3%,在检验HbA1c和体重的优效性之前先检验非劣效性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者指出需进一步研究评估其在临床环境中的有效性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Phase 3 trials have not compared oral semaglutide, a glucagon-like peptide 1 receptor agonist, with other classes of glucose-lowering therapy. OBJECTIVE: To compare efficacy and assess long-term adverse event profiles of once-daily oral semaglutide vs sitagliptin, 100 mg added on to metformin with or without sulfonylurea, in patients with type 2 diabetes. DESIGN, SETTING, AND PARTICIPANTS: Randomized, double-blind, double-dummy, parallel-group, phase 3a trial conducted at 206 sites in 14 countries over 78 weeks from February 2016 to March 2018. Of 2463 patients screened, 1864 adults with type 2 diabetes uncontrolled with metformin with or without sulfonylurea were randomized. INTERVENTIONS: Patients were randomized to receive once-daily oral semaglutide, 3 mg (n = 466), 7 mg (n = 466), or 14 mg (n = 465), or sitagliptin, 100 mg (n = 467). Semaglutide was initiated at 3 mg/d and escalated every 4 weeks, first to 7 mg/d then to 14 mg/d, until the randomized dosage was achieved. MAIN OUTCOMES AND MEASURES: The primary end point was change in glycated hemoglobin (HbA1c), and the key secondary end point was change in body weight, both from baseline to week 26. Both were assessed at weeks 52 and 78 as additional secondary end points. End points were tested for noninferiority with respect to HbA1c (noninferiority margin, 0.3%) prior to testing for superiority of HbA1c and body weight. RESULTS: Among 1864 patients randomized (mean age, 58 [SD, 10] years; mean baseline HbA1c, 8.3% [SD, 0.9%]; mean body mass index, 32.5 [SD, 6.4]; n=879 [47.2%] women), 1758 (94.3%) completed the trial and 298 prematurely discontinued treatment (16.7% for semaglutide, 3 mg/d; 15.0% for semaglutide, 7 mg/d; 19.1% for semaglutide, 14 mg/d; and 13.1% for sitagliptin). Semaglutide, 7 and 14 mg/d, compared with sitagliptin, significantly reduced HbA1c (differences, -0.3% [95% CI, -0.4% to -0.1%] and -0.5% [95% CI, -0.6% to -0.4%], respectively; P < .001 for both) and body weight (differences, -1.6 kg [95% CI, -2.0 to -1.1 kg] and -2.5 kg [95% CI, -3.0 to -2.0 kg], respectively; P < .001 for both) from baseline to week 26. Noninferiority of semaglutide, 3 mg/d, with respect to HbA1c was not demonstrated. Week 78 reductions in both end points were statistically significantly greater with semaglutide, 14 mg/d, vs sitagliptin. CONCLUSIONS AND RELEVANCE: Among adults with type 2 diabetes uncontrolled with metformin with or without sulfonylurea, oral semaglutide, 7 mg/d and 14 mg/d, compared with sitagliptin, resulted in significantly greater reductions in HbA1c over 26 weeks, but there was no significant benefit with the 3-mg/d dosage. Further research is needed to assess effectiveness in a clinical setting. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02607865.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Rosenstock J, Allison D, Birkenfeld AL, et al. Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial. JAMA. 2019. PMID: 30903796. doi:10.1001/jama.2019.2942

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。